Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

135.22 -3.86 (-2.78%)
Streaming Delayed Price Updated: 3:04 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 263,146
Open 138.75
Bid (Size) 135.16 (1)
Ask (Size) 135.43 (2)
Prev. Close 139.08
Today's Range 133.30 - 138.75
52wk Range 59.58 - 146.86
Shares Outstanding 55,137,429
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Glaukos?
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga

Performance

YTD
+75.43%
+75.43%
1 Month
+2.92%
+2.92%
3 Month
+1.67%
+1.67%
6 Month
+18.26%
+18.26%
1 Year
+111.25%
+111.25%

More News

Read More
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
Via Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
How Is The Market Feeling About Glaukos?
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Glaukos
Via Benzinga
Navigating 11 Analyst Ratings For Glaukos
Via Benzinga
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Via Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
From Glaukos Corporation
Via Business Wire
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
Via Benzinga
10 Analysts Have This To Say About Glaukos
Via Benzinga
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
Via Benzinga
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
7 Leading MedTech Stocks for Next-Gen Health Solutions
Via InvestorPlace
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
From Glaukos Corporation
Via Business Wire
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.